Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 Aug 6;19(10):2503–2515. doi: 10.1158/1055-9965.EPI-10-0391

Table 2.

Relative risk (and 95% confidence interval) of breast, endometrial, and ovarian cancers by quintile of calorie-adjusted acrylamide intake, 1980–2006

Quintile of calorie-adjusted acrylamide intake
Q1 (low) Q2 Q3 Q4 Q5 (high) p-value
Median intake (mcg/d) 8.7 12.7 15.7 19.0 25.1 for trend
BREAST CANCER
Num. cases 1282 1280 1331 1287 1121
Person-years 405,391 404,518 404,349 404,769 405,644
Age-adjusted RR* 1.00 0.94 (0.87–1.02) 0.99 (0.92–1.07) 0.99 (0.91–1.07) 0.94 (0.87–1.02) 0.36
Multivariable RR 1.00 0.93 (0.86–1.01) 0.98 (0.91–1.06) 0.98 (0.90–1.06) 0.95 (0.87–1.03) 0.50
Never smokers only
 Num. cases 652 610 582 516 392
 Person-years 210,666 198,085 187,783 171,665 151,532
 Age-adjusted RR* 1.00 0.94 (0.84–1.05) 0.96 (0.86–1.08) 0.96 (0.85–1.08) 0.90 (0.80–1.03) 0.21
 Multivariable RR 1.00 0.91 (0.81–1.02) 0.93 (0.83–1.05) 0.94 (0.84–1.06) 0.89 (0.78–1.02) 0.18

ENDOMETRIAL CANCER
Num. cases 88 100 106 102 88
Person-years 277,776 277,073 276,839 277,409 277,789
Age-adjusted RR* 1.00 1.07 (0.80–1.43) 1.17 (0.88–1.56) 1.15 (0.86–1.54) 1.12 (0.83–1.52) 0.41
Multivariable RR 1.00 1.12 (0.83–1.50) 1.31 (0.97–1.77) 1.35 (0.99–1.84) 1.41 (1.01–1.97) 0.03
Never smokers only
 Num. cases 53 47 59 56 42
 Person-years 144,400 135,320 128,534 116,601 102,813
 Age-adjusted RR* 1.00 0.93 (0.63–1.39) 1.30 (0.89–1.90) 1.37 (0.93–2.01) 1.31 (0.86–2.00) 0.06
 Multivariable RR 1.00 0.97 (0.64–1.46) 1.35 (0.90–2.02) 1.47 (0.97–2.24) 1.43 (0.90–2.28) 0.04

OVARIAN CANCER
Num. cases 87 75 95 81 78
Person-years 246,187 245,523 245,327 245,667 246,155
Age-adjusted RR* 1.00 0.85 (0.62–1.16) 1.10 (0.81–1.47) 0.95 (0.70–1.29) 1.00 (0.73–1.37) 0.78
Multivariable RR§ 1.00 0.93 (0.68–1.29) 1.29 (0.94–1.76) 1.17 (0.84–1.64) 1.25 (0.88–1.77) 0.12
Never smokers only
 Num. cases 40 38 31 24 23
 Person-years 126,888 118,416 112,475 101,849 91,082
 Age-adjusted RR* 1.00 1.03 (0.65–1.63) 0.92 (0.57–1.48) 0.82 (0.49–1.37) 0.92 (0.54–1.55) 0.53
 Multivariable RR§ 1.00 1.17 (0.72–1.88) 1.04 (0.63–1.74) 1.11 (0.63–1.94) 1.19 (0.66–2.15) 0.63
*

Age-adjusted models are adjusted for age in months and calendar year.

Breast cancer multivariable models additionally adjusted for: smoking (never, past <25 cig/d, past 25+ cig/d, current <25 cig/d, current 25+ cig/d), BMI (<18.5, 18.5 to <20, 20 to <22.5, 22.5 to <25, 25 to <30, 30+), height (quartiles), menopausal status/age at menopause/PMH use (premenopausal, uncertain status, postmenopausal: age at menopause <45, 45–52, or >52 AND PMH use never, former, current <5 years, or current 5+ years), parity and age at first birth (nulliparous, parity 1–2 and age first birth <25, parity 1–2 age first birth 25-<30, parity 1–2 age first birth 30+, parity 3–4 age first birth <25, parity 3–4 age first birth 25-<30, parity 3–4 age first birth 30+, parity 5+ age first birth <25, parity 5+ age first birth 25+) family history of breast cancer (yes/no), benign breast disease (yes/no), age at menarche (<13, 13, 14+), physical activity (<=18 met-h/wk, >18 met-h/wk), folate, glycemic index, and animal fat intake (quintiles), alcohol (continuous, g/day), energy intake (continuous, kcal/d).

Endometrial cancer multivariable models additionally adjusted for: smoking (see categories for breast cancer), BMI (<20, 20-<21, 21-<22, 22-<23, 23-<24, 24-<25, 25-<27, 27-<29, 29-<30, 30-<32, 32-<35, 35-<40, 40+), age at menarche (<13, 13, 14+), menopausal status/age at menopause/PMH use (see categories for breast cancer), parity (nulliparous, 1–2, 3–4, 5+), oral contraceptive use (never, 0–3 years of use, >3-<5 years, 5+ years of use), high blood pressure (yes/no), diabetes (yes/no), physical activity (<=18 met-h/wk, >18 met-h/wk), caffeine intake (quintiles), energy intake (continuous, kcal/d).

§

Ovarian cancer multivariable models additionally adjusted for: smoking (see categories for breast cancer), BMI (see categories for breast cancer), parity (see categories for endometrial cancer), oral contraceptive use (see categories for endometrial cancer), menopausal status and PMH use (premenopausal, uncertain status, postmenopausal and never used PMH, postmenopausal and former PMH, postmenopausal and current PMH use), tubal ligation (yes/no), physical activity (<=18 met-h/wk, >18 met-h/wk), caffeine intake (quintiles), energy intake (continuous, kcal/d).